SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE:CTLT), the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced that it has launched an underwritten public offering of $550 million of its common stock. In connection with the Offering, Catalent intends to grant the underwriter an option for 30 days to purchase up to $82.5 million of additional shares of its common stock.

Catalent intends to use the net proceeds from the Offering to repay in full the $200.0 million of outstanding borrowings under the revolving credit facility under its senior secured credit facilities and for general corporate purposes, which may include, without limitation and in Catalent’s sole discretion, working capital, capital expenditures, and funding its growth strategy through organic investments and potential future acquisitions.

RBC Capital Markets is acting as sole underwriter for the Offering.